[{"id":"4bef796b-b171-4b4a-a80a-d9b7dc98b70c","acronym":"PIKASSO-01","url":"https://clinicaltrials.gov/study/NCT05307705","created_at":"2022-04-01T20:54:05.809Z","updated_at":"2025-02-25T16:17:30.808Z","phase":"Phase 1","brief_title":"A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors","source_id_and_acronym":"NCT05307705 - PIKASSO-01","lead_sponsor":"Eli Lilly and Company","biomarkers":" HER-2 • ER • PIK3CA","pipe":" | ","alterations":" HER-2 negative • PIK3CA mutation","tags":["HER-2 • ER • PIK3CA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • PIK3CA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • Verzenio (abemaciclib) • fulvestrant • letrozole • anastrozole • exemestane • Inluriyo (imlunestrant) • LOXO-783"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 193","initiation":"Initiation: 05/11/2022","start_date":" 05/11/2022","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 05/01/2025","study_completion_date":" 05/01/2025","last_update_posted":"2024-10-26"}]